Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors

Adeno-associated virus (AAV) vectors are a cornerstone of modern gene therapy, valued for their ability to provide long-term, stable transgene expression. However, AAV therapy is hindered by a limited packaging capacity and the lack of a simple, safe, and non-immunogenic mechanism to precisely regulate transgene levels post-delivery. Traditional control systems often rely on exogenous proteins that are themselves immunogenic and occupy valuable space within the limited AAV genome. Riboswitches—structured nucleic acid elements that change conformation upon ligand binding to modulate gene expression—offer a promising, compact, and non-immunogenic alternative for in vivo gene control.

Riboswitches regulate gene expression at various stages, including pre-mRNA splicing, polyadenylation, translational initiation, and ribosomal frameshifting. In the context of AAV delivery, aptazyme riboswitches—which combine an aptamer ligand-sensing domain with a self-cleaving ribozyme—are particularly prominent. These devices can act as 'on' or 'off' switches, either inducing expression or triggering mRNA degradation in the presence of specific small molecules.

Beyond simple expression control, these devices are increasingly integrated into complex therapeutic architectures, such as CRISPR-Cas systems, where they regulate the activity of guide RNAs or effector proteins. By incorporating these switches, researchers can achieve tissue-specific control, limit the toxicity of therapeutic products, and improve vector manufacturing yields by suppressing transgene expression during production phases.

While riboswitches function robustly in bacteria, their performance in mammalian cells remains a major hurdle. Factors such as cellular ion concentrations, molecular crowding, and the unique landscape of eukaryotic RNA-binding proteins can impede the function of switches derived from prokaryotic sequences. Current research is heavily focused on overcoming these barriers through rational design and high-throughput screening. Recent innovations, such as the use of barcoded library screening and automated selection methods like DRIVER and CleaveSeq, are facilitating the discovery of new riboswitches that perform well in human cell environments.

Looking forward, the goal is to optimize these devices to respond to FDA-approved therapeutic small molecules, ensuring that the control mechanism itself does not introduce new toxicity or safety risks, thereby enhancing the precision and safety profile of next-generation gene therapies.